Stock Events

Stock Events

Ab Science 

$0.8518
59
+$0.00+0%Tuesday 13:26

Statistics

Day High
2.7
Day Low
2.7
52W High
2.7
52W Low
1.12
Volume
1,452
Avg. Volume
18
Mkt Cap
74.33M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Oct 9Expected
Q1 2021
Q1 2024
Q2 2024
Q1 2025
Q3 2025
Q1 2026
Q3 2026
-0.15
-0.1
-0.05
0
Expected EPS
-0.0799442
Actual EPS
-0.1484678

Financials

-134.38%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
1.38MRevenue
-1.85MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ABSCF. It's not an investment recommendation.
TotalEnergies
8
TTE.PA
Stellantis N.V
8
STLAP.PA
Air Liquide
8
AI.PA
Innate Pharma
8
IPH.PA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap211.7B
Gilead Sciences is a biopharmaceutical company that competes with AB Science in the development of treatments for various diseases, including those in oncology and inflammatory diseases, areas where AB Science is also active.
Novartis
NVS
Mkt Cap303.67B
Novartis is a global healthcare company that competes across multiple segments, including those targeted by AB Science, such as cancer and chronic inflammatory diseases, with a broad portfolio of drugs.
AMGEN
AMGN
Mkt Cap251.94B
Amgen is a biotech company focusing on human therapeutics, with products that compete in the oncology and inflammatory disease markets, directly competing with AB Science's research and drug development efforts.
Pfizer
PFE
Mkt Cap173.95B
Pfizer is a research-based biopharmaceutical company with a wide range of products that compete with AB Science, especially in the fields of oncology and immunology.
Roche
RHHBY
Mkt Cap334.28B
Roche Holding AG is a healthcare company that competes with AB Science in developing treatments for various diseases, including cancer and chronic inflammatory conditions, through its biotechnology and pharmaceutical divisions.
Bristol-Myers Squibb
BMY
Mkt Cap127.71B
Bristol-Myers Squibb is a global biopharmaceutical company with a focus on discovering, developing, and delivering innovative medicines that compete with AB Science's portfolio, especially in cancer and immune-inflammatory diseases.
Merck
MRK
Mkt Cap368.89B
Merck & Co., Inc. is known for its contributions to healthcare and pharmaceuticals, competing with AB Science in areas such as oncology, making it a direct competitor in the development of cancer treatments.
Lilly(Eli) &
LLY
Mkt Cap1.26T
Eli Lilly and Company is a global pharmaceutical company that develops drugs in areas like oncology and autoimmune diseases, competing with AB Science in the development and marketing of treatments for similar conditions.
Regeneron Pharmaceuticals
REGN
Mkt Cap95.99B
Regeneron Pharmaceuticals is a biotechnology company that competes with AB Science in the development of medicines for the treatment of serious medical conditions, including oncology and inflammatory diseases.
Astrazeneca
AZN
Mkt Cap289.48B
AstraZeneca is a multinational pharmaceutical and biopharmaceutical company with a wide range of therapeutic products, competing with AB Science in areas such as oncology and respiratory diseases.

About

AB Science S.A. is a pharmaceutical firm focused on discovering, advancing, and commercializing protein kinase inhibitors for both human and animal therapeutic applications. The company's primary drug candidate, masitinib, a tyrosine kinase inhibitor, is currently undergoing late-stage (Phase III) clinical investigations for various conditions including prostate and pancreatic cancers, amyotrophic lateral sclerosis (ALS), multiple sclerosis, Alzheimer's disease, severe asthma, and mastocytosis. Additionally, it is in Phase II trials for managing Covid-19. Beyond masitinib, AB Science is also advancing AB8939, a synthetic microtubule destabilizer designed to treat acute myeloid leukemia. Another product in development is AB20001, a combination therapy involving masitinib and isoquercetin, which is currently in Phase II trials to assess its safety and effectiveness in hospitalized patients experiencing moderate to severe COVID-19. In the European market, masitinib is sold under the brand name Masivet. Established in 2001, AB Science S.A. operates from its headquarters in Paris, France.
Show More
CEO
Stéphane Ledermann
Employees
36
Country
France
ISIN
FR0010557264
WKN
000A1CXBG

Listings

PA
FR
ABBS.PA
PA
FR
ABSBS.PA
STU
DE
A8D.STU
MU
DE
A8D.MU

0 Comments

Share your thoughts

FAQs

What is Ab Science stock price today?▼
The current price of ABSCF is $0.85 USD — it has increased by +0% in the past 24 hours. Watch Ab Science stock price performance more closely on the chart.
What is Ab Science stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange Ab Science stocks are traded under the ticker ABSCF.
Is Ab Science stock price growing?▼
ABSCF stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Ab Science has showed a -11.11% decrease.
What is Ab Science market cap?▼
Today Ab Science has the market capitalization of 74.33M
When is the next Ab Science earnings date?▼
Ab Science is going to release the next earnings report on April 23, 2027.
What were Ab Science earnings last quarter?▼
ABSCF earnings for the last quarter are -0.15 USD per share, whereas the estimation was -0.08 USD resulting in a -85.71% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Ab Science revenue for the last year?▼
Ab Science revenue for the last year amounts to 1.38M USD.
What is Ab Science net income for the last year?▼
ABSCF net income for the last year is -1.85M USD.
How many employees does Ab Science have?▼
As of November 6, 2026, the company has 36 employees.
In which sector is Ab Science located?▼
Ab Science operates in the Health & Wellness sector.
When did Ab Science complete a stock split?▼
Ab Science has not had any recent stock splits.
Where is Ab Science headquartered?▼
Ab Science is headquartered in Paris, France.